Terry Sablatura, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 109 Shult Dr, Suite 206, Columbus, TX 78934 Phone: 979-732-8280 Fax: 979-732-9740 |
Brooke Renee Adamek, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 2122 Highway 71 S, Columbus, TX 78934 Phone: 979-732-5783 |
Anne Elizabeth Masarik, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 109 Shult Dr Ste 206, Columbus, TX 78934 Phone: 979-732-8280 |
Rachal Post, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1024 Milam St, Columbus, TX 78934 Phone: 979-732-8280 Fax: 979-732-9740 |
Julie Hrachovy, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1024 Milam St, Columbus, TX 78934 Phone: 979-732-8280 Fax: 979-732-9740 |
Sds Physical Therapy Lp Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2122 Hwy 71 South, #103, Columbus, TX 78934 Phone: 979-732-8280 Fax: 979-732-9740 |
Kimberly Berger Brandt, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 109 Shult Dr, Suite 206, Columbus, TX 78934 Phone: 979-732-8280 Fax: 979-732-9740 |
News Archive
In this post in PSI's "Healthy Living" blog, Mannasseh Phiri, PSI's country representative in Zambia, examines HIV/AIDS in Zambian prisons. Phiri reports the findings of a survey recently conducted by the IN BUT FREE (IBF) Prisons Project "to determine the extent and magnitude of the HIV and AIDS epidemic in Zambia's prisons."
Researchers at the Rabin Medical Center in Israel have determined that the use of drug-eluting stents (DES) improves the long-term clinical outcome for patients undergoing percutaneous coronary intervention (PCI), commonly known as angioplasty. Results of this study appear in the September issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.
International Stem Cell Corporation, today announced that its stem cell therapeutic programs focused on protective, transparent corneas (CytoCor™) in the front of the eye and the light-sensitive retinal tissue (CytoRet™) in the back of the eye will be formalized into a new business unit, Cytovis™.
AMAG Pharmaceuticals, Inc. today announced positive new data from the FIRST head-to-head trial comparing Feraheme (ferumoxytol) Injection for intravenous (IV) use to iron sucrose in patients with iron deficiency anemia and chronic kidney disease.
› Verified 4 days ago